Clinical trial

Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary…

NCT00140101 · Abbott Medical Devices, Industry · Completed

Key facts

NCT number NCT00140101
Title Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
Official title A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System as Compared to the TAXUS™ Express2™ Paclitaxel-Eluting Stent in de Novo Coronary Artery Lesions
Acronym ZoMaxx™ II
Lead sponsor Abbott Medical Devices, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Intervention type Device
Interventions ZoMaxx™ Drug-Eluting Coronary Stent System, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Enrollment 1,099
Start date May 1, 2005
Primary completion Sep 1, 2007
Completion Jan 1, 2012
First posted Sep 1, 2005
Last update posted Jan 10, 2012
Countries Australia, Germany, New Zealand, United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies